5, 7-Dihydroxy-4′-methoxyflavones represent a new class of selective reversible MAO-B inhibitors with potential therapeutic application for treatment of neurodegenerative disorders, including Parkinson’s disease in combination with standard drugs [28]. Here, MAOB is linked to Parkinson disease.